Kornimate/medical-research-clean huggingface dataset:
maladaptive psychosocial beliefs and adolescents with patellofemoral pain

Conditions: Patellofemoral Pain Syndrome; Knee Pain Chronic; Patellofemoral Syndrome; Anterior Knee Pain Syndrome

Summary: this is a randomized prospective study assessing the impact of psychosocial factors on pain and physical performance among adolescents with patellofemoral pain. a set of psychosocial surveys assessing fear avoidance beliefs, kinesiophobia, and pain catastrophizing will be completed by the participant/parents. participants will then complete an activity questionnaire, numeric pain rating scale, and a self-report questionnaire of functional ability. participants will then be randomized into one of two groups (psychologically informed education group and a control group). participants will view a series of educational videos (based upon group assignment) and complete physical therapy exercises for lower extremity strengthening, flexibility, and neuromuscular control. participants with patellofemoral pain will then complete follow-up surveys of their psychosocial beliefs, pain and self-reported functional ability through redcap at immediately post-intervention, 1 week, 3 weeks, 6 weeks, and 3 months.


Eligibility criteria:
inclusion criteria: • having patellofemoral pain as defined as: pain around or behind the patella, which is aggravated by at least one activity that loads the patellofemoral joint during weight bearing on a flexed knee (e.g., squatting, stair ambulation, jogging/running, hopping/jumping). exclusion criteria: * prior history of patellar dislocation. * suspicion of other diagnosis of the knee by evaluating physical therapist or principal investigator. * other concomitant injury of the leg. * prior history of knee surgery. * red flags present for non-musculoskeletal involvement (bowel/bladder problems, saddle anesthesia, progressive neurological deficits, recent fever or infection, unexplained weight loss, unable to change symptoms with mechanical testing). * numbness and tingling in any lumbar dermatome.

Keywords: knee adolescent psychologically-informed anterior knee pain
an observational study of glucocorticoid use in patients with rheumatoid arthritis on treatment with roactemra/actemra (tocilizumab)

Conditions: Rheumatoid Arthritis

Summary: this observational study will evaluate the glucocorticoid sparing effect after 12 months of treatment with roactemra/actemra (tocilizumab) in patients with rheumatoid arthritis. data will be collected for 12 months after the initiation of treatment with roactemra/actemra from patients who had been on treatment with \>5 mg prednisone or equivalent for at least 3 months .


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * patients with rheumatoid arthritis for whom the rheumatologist decided to introduce roactemra * patients taking more than 5 mg/day of oral prednisone (or equivalent) for at least 3 months exclusion criteria: * participation in a clinical trial in rheumatoid arthritis
study to evaluate the effect of secukinumab compared to placebo on aortic vascular inflammation in subjects with moderate to severe plaque psoriasis

Conditions: Chronic Plaque Psoriasis

Summary: this study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.


Eligibility criteria:
inclusion criteria: - males and females at least 18 years of age with moderate to severe plaque psoriasis exclusion criteria: * forms of psoriasis other than chronic plaque psoriasis * previous exposure to il-17a or il-17 receptor targeting agents. * other active or ongoing disease that may interfere with evaluation of psoriasis or places the patient at unacceptable risk * other protocol-defined inclusion/exclusion criteria may apply

Keywords: psoriasis plaque psoriasis secukinumab ain457 biologic monoclonal antibody aortic vascular inflammation
impedance spectroscopy in esophageal cancer

Conditions: Cancer of Esophagus

Summary: detection of early esophageal cancer in surrounding normal tissue can be challenging even for experienced examiners. the early detection is essential to determine the following treatment. early stages of esophageal cancers can be treated by endoscopic resection whereas advanced neoplasia might lead to an operation of the esophagus. diagnosis is made usually by biopsies of suspicious lesions or untargeted quadrant biopsies. the electrical properties in inflammatory tissue and cancer can be sensed by electrical bioimpedance technique. the aim of this study is to compare the impedance probe with the histological result and to investigate the feasibility of the new technique in detection of esophageal cancer.

detection of early esophageal cancer in surrounding normal tissue can be challenging even for experienced examiners. the early detection is essential to determine the following treatment. early stages of esophageal cancers can be treated by endoscopic resection (er) whereas advanced neoplasia might lead to esophagectomy. diagnosis is made usually by biopsies of suspicious lesions or untargeted quadrant biopsies. the electrical properties in inflammatory tissue and dysplasia can be sensed by electrical bioimpedance technique. the aim of this study is to compare the impedance probe with the histological result and to investigate the feasibility of the new technique in detection of esophageal cancer.

Eligibility criteria:
inclusion criteria: known esophageal cancer and planned for endoscopic resection exclusion criteria: 1. missing consent / agreement 2. patient in bad condition for endoscopy or endoscopic resection 3. patients with coagulopathy or anticoagulative medication which is a contraindication for endoscopy

Keywords: impedance, barrett´s cancer, early detection of cancer
clinical evaluation of the ap203 plant extract mixture in adult patients with increased incidence of viral and/or bacterial upper respiratory tract infections

Conditions: Upper Respiratory Tract Infection Bacterial

Summary: the aim of the study was to assess the efficacy and safety of ap203 preparation (rescovin®) in a group of patients with increased incidence to viral and/or bacterial upper respiratory tract infections.

randomized, double-blind, cross over study conducted under medical supervision on 1) group of 30 patients receiving ap203 mixture in capsule form and 2) group of 30 receiving placebo. after a washout period a group receiving placebo receiver ap203 mixture in syrup form. the study group was adult patients with an increased incidence of upper respiratory tract infection. during the study, the effect of a mixture of ap203 extracts (rescovin®) on markers of inflammation and oxidative stress and the effect on the incidence of upper respiratory tract infections was assessed.

Eligibility criteria:
inclusion criteria: * women and men, 18-70 years old * healthy patients at the time of enrollment to the study (without active upper respiratory tract infection) * presence of 2 or more episodes of upper respiratory tract infections or \>=2 episodes of cold during the year * patients with chronic upper respiratory tract diseases including bronchial asthma * signed informed consent * women: contraception or postmenopausal age exclusion criteria: * intake of supplements containing plant extracts, polyphenols or anthocyanins for the 3 months prior to the study initiation * acute inflammation * oral immunosuppressive drugs * steroid, anti-allergic drugs in exacerbations of chronic disease at least 2 months from the start of study participation * antibiotic therapy 1 month prior to study initiation * participation in another clinical trial; * oncological disease, autoimmune disease, severe liver dysfunction, tuberculosis, leukaemia, multiple sclerosis, aids, rheumatoid arthritis, organ transplantation; * hypersensitivity/allergy to any of the ingredients of the product, allergy to plants of the asteraceae family (e.g. chamomile, calendula); * women who are pregnant or planning to become pregnant during the study period;

Keywords: upper respiratory tract infections bacterial infections viral infections rescovin plant extract chokeberry extract echinacea extract
ketamine in robot-assisted thyroidectomy

Conditions: Thyroid; Acute Pain; Chronic Pain

Summary: in this prospective double-blinded study, the investigators compared acute postoperative pain and rescue analgesic demand during postoperative period after robot thyroidectomy between ketamine and placebo groups.

robot-assisted endoscopic thyroidectomy has been popularized due to cosmetic advantages. despite small incisions, robot thyroidectomy did not offer satisfactory reduction in postoperative pain compared to open thyroidectomy. ketamine is a non-competitive n-methyl-d-aspartate (nmda) receptor blocker and takes some attractive advantages in terms of pain control. when low dose ketamine is perioperatively administrated, opioid sparing effect during postoperative period is reported in various surgical procedures such as spine, thoracic, and gynecologic surgery. ketamine's beneficial effect on postoperative pain has not been investigated in patients undergoing robot thyroidectomy. the investigators hypothesized that perioperative ketamine administration can reduce acute postoperative pain after robot thyroidectomy and the incidence of chronic pain hypoesthesia on anterior chest at 3 months after surgery.

Eligibility criteria:
inclusion criteria: * patients scheduled for robot-assisted thyroidectomy * asa i-iii exclusion criteria: * patients with renal dysfunction * patients with hepatic dysfunction * patients with neurologic dysfunction * patients with the history of drug addiction * patients with chronic pain * patients who are allergic to ketamine * patients with increased ocular or intracranial pressure * patients with the risk of aspiration

Keywords: thyroidectomy endoscopy ketamine acute pain chronic pain postoperative period
first line treatment of metastatic pancreatic cancer: sequential nab-paclitaxel + gemcitabine/folfiri.3 vs nab-paclitaxel + gemcitabine

Conditions: Metastatic Pancreatic Cancer

Summary: the main objective of this trial is to evaluate every 2 months alternating nab-paclitaxel/gemcitabine and folfiri.3 versus nab-paclitaxel + gemcitabine, regarding the progression of disease at 6 months.


Eligibility criteria:
inclusion criteria: * histological or cytological confirmation of pancreatic adenocarcinoma * distant metastatic disease * scan (or mri if scanner contraindicated) completed within 3 weeks of the start of treatment * at least one lesion measurable by recist v1.1 criteria * life expectancy\> 3 months * no previous chemotherapy (adjuvant chemotherapy with gemcitabine authorised if administered more than 6 months prior to inclusion) * no previous radiotherapy (unless at least one measurable target lesion outside the irradiation zone) * pain must be monitored before inclusion * 18 years \< age \< 75 * performance status: who \< 2 * anc ≥ 1500/mm3, platelets ≥ 100 000/mm3, haemoglobin ≥ 9 g/dl * asat (sgot), alat (sgpt) ≤ 2.5 x uln or ≤ 5 x uln if liver metastases found * bilirubin ≤ 1.5 x uln (patients drained by retrograde technique are includable), creatinine \ 60 ml/min * women of childbearing age must have a negative pregnancy test (β hcg) before starting treatment * women of childbearing age as well as men (who have sexual intercourse with women of childbearing age) must agree to use effective contraception without interruption for the duration of treatment and 6 months after the administration of the last treatment dose * patient affiliated to the social security scheme * patient information and signature of informed consent exclusion criteria: * - other types of pancreatic tumours, especially endocrine or acinar cell tumours * ampulloma * presence of meningeal or cerebral metastases, bone metastases * gilbert's syndrome * presence of neuropathy\> grade 1 according to ncic-ctc 4.0 * contraindications specific to the studied treatments * history of chronic diarrhoea or inflammatory disease of the colon or rectum, or of unresolved occlusion or sub-occlusion for which symptomatic treatment is being administered * other concomitant cancer or history of cancer during the 5 years, with the exception of a carcinoma in situ of the cervix or basal cell or squamous cell carcinoma, considered cured * significant history of heart or respiratory disease, including any history of interstitial pneumonia * patient already included in another clinical trial with an experimental molecule * women who are breast-feeding * persons deprived of liberty or under guardianship * unable to submit to medical monitoring during the trial due to geographical, social or psychological reasons

Keywords: pancreatic cancer
safety and efficacy study of epitope peptide to treat hla-a*02 disease controlled advanced non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the investigators previously identified a novel hla-a\*0201-restricted epitope peptide, which was derived from a cancer-testis antigen, urlc10 as a target for vaccination against lung cancer. in this clinical study, the investigators examine using the peptides the safety, immunogenicity, and antitumor effect of vaccine treatment to prevent relapse of the disease for hla-a\*0201-positive advanced non-small cell lung cancer patients whose disease are controlled after any standard therapies.

the purpose of this study is to evaluate the safety, tolerability, immune response and clinical efficacies of hla-a\*0201 restricted epitope peptides urlc10 emulsified with montanide isa 51 for disease controlled advanced non-small cell lung cancers. the investigators previously identified a novel hla-a\*0201-restricted epitope peptide, which was derived from a cancer-testis antigen, urlc10 as a target for cancer vaccination against lung cancer. in this phase i/ii trial, the investigators examine using the peptides the safety, immunogenicity, and antitumor effect of vaccine treatment for hla-a\*0201-positive advanced non-small cell lung cancer patients whose disease are controlled after any standard therapies, but who do not have any options for additional standard ones to prevent .future relapse of the disease.

Eligibility criteria:
inclusion criteria: 1. nsclc whose disease are controlled after any standard therapies, but who do not have any additional standard ones to prevent .future relapse of the disease. 2. ecog performance status 0-2 3. age between 20 to 85 4. clinical efficacy can be evaluated by some methods 5. no prior chemotherapy, radiation therapy, hyperthermia or immunotherapy within appropriate periods 6. life expectancy \> 3 months 7. laboratory values as follows 1500/mm3 \ 75000/mm3 asparate transaminase \< 3 x cutoff value alanine transaminase \< 3 x cutoff value total bilirubin \< 3 x cutoff value serum creatinine \< 2x cutoff value 8. hla-a\*0201 9. able and willing to give valid written informed consent exclusion criteria: 1. active and uncontrolled cardiac disease (i.e. coronary syndromes, arrhythmia) 2. myocardial infarction within six months before entry 3. breastfeeding and pregnancy (woman of child bearing potential) 4. active and uncontrolled infectious disease 5. concurrent treatment with steroids or immunosuppressing agent 6. other malignancy requiring treatment 7. non-cured traumatic wound 8. decision of unsuitableness by principal investigator or physician-in-charge
in vitro study of [18f]f-fapi-74 feasibility in vulvar cancer

Conditions: Vulvar Squamous Cell Carcinoma

Summary: this study aims to investigate the expression of fap by phosphor imaging in invasive vulvar squamous cell carcinoma specimens. this in vitro study will include all consecutive tumour specimens stored both in optimal cutting temperature (oct) compound and formalin-fixed paraffin-embedded (ffpe) from patients with a first diagnosis of vulvar squamous cell carcinoma who underwent surgery at fondazione policlinico universitario a. gemelli irccs, rome, italy.

vulvar cancer is a rare gynaecological tumour, affecting 2.5 out of 100,000 women per year. the most common histological type is squamous cell carcinomas. current guidelines suggest 2-\[18f\]fluoro-2-deoxy-d-glucose (\[18f\]fdg) pet/ct for t2 or larger tumours or when metastases are suspected, even though few studies showed controversial results on small series about the diagnostic accuracy of \[18f\]fdg pet/ct for vulvar cancer. the recently developed fibroblast activation protein inhibitor (fapi), labelled with gallium-68 or fluorine-18, may be a promising diagnostic tool for gynaecological cancers in the field of pet/ct imaging. there is an unmet need to characterize fap expression at the whole-body level, to assess target expression for disease detection and fap-directed therapies. this study aims to investigate the expression of fap by phosphor imaging in vulvar squamous cell carcinoma specimens on oct compound and ffpe sections.

Eligibility criteria:
inclusion criteria: * patients with histologically confirmed diagnosis of invasive vulvar cancer with squamous cell histotype, both from primary tumour site and excised metastatic lns. * availability of both ffpe and oct stored samples from each primary tumour site and (when available) from the corresponding metastatic groin lymph nodes. * samples stored in sufficient quantity not to be completely exhausted by their use for this study. * optimal stored sample * available clinical and histopathological data exclusion criteria: - coexistence of primary tumours other than vulvar cancer

Keywords: vulvar squamous cell carcinoma fapi phosphor imaging
exploratory study to evaluate 2 acupuncture methods for the treatment of headaches associated with tbi

Conditions: Headache; Traumatic Brain Injury

Summary: this study investigates whether acupuncture can help to decrease the number and severity of headaches in people who have traumatic brain injury. the aim of this study is to compare two different types of acupuncture-either traditional chinese acupuncture or ear acupuncture-to a group that receives no acupuncture at all. acupuncture has been demonstrated to reduce pain, improve health-related quality of life, prevent migraine headaches, and improve tension and chronic daily headaches.

this is a 12 week study. if eligible, participants will be randomly assigned to 1of 3 groups: ear acupuncture, traditional chinese acupuncture, or the usual care group. subjects receiving acupuncture will: * meet with one of the acupuncturists who will conduct her first assessment * come to walter reed army medical center (wramc) 10 times over a 6-week period to receive acupuncture treatments from a licensed acupuncturist subjects in the usual care group will: * not receive any acupuncture treatments * continue usual treatment plan * be given the option to receive 10 acupuncture treatments between the 6- and 12-week period all subjects will also: * complete questionnaires at 3 different times: baseline (beginning of study), after 6 weeks, and after 12 weeks. these questionnaires will assess headaches, overall health and quality of life * complete a daily headache diary * continue to be treated for their headaches * continue taking prescription and over-the-counter medications for any conditions being treated

Eligibility criteria:
inclusion criteria: 1. 18-69 years of age 2. service members with previous deployment to war zone 3. non-acute mild to moderate traumatic brain injury as defined by: * injury event (i.e., blast, fall, mvc, head impact) that occurred at least 7 days prior * loss of consciousness (if present) for less than 24 hours and alteration of consciousness or posttraumatic amnesia for less than one week 4. presence of headache or any etiology requiring self-medication or medical management with at least 4 headache days in the past 4 weeks 5. rancho los amigos cognitive scale score of greater than or equal to 7 6. able to provide informed consent exclusion criteria: 1. acupuncture treatment for any reason within the past month 2. any active unstable psychiatric condition, including active psychosis, suicidal or homicidal ideation 3. unwillingness on the part of the participant to complete all study visits and/or components of the intervention 4. scheduled surgery during the treatment phase of the study 5. pregnancy or breastfeeding at time of study enrollment or during study participation 6. any medically unstable condition that in the opinion of the p.i. has the potential to warrant inpatient treatment in the medical or intensive care units 7. inability to give informed consent or complete study measures

Keywords: tbi headaches military acupuncture walter reed army medical center fort belvoir community hospital
robot-assisted laparoscopic partial nephrectomy via the extraperitoneal approach in the prone position versus the lateral position

Conditions: Renal Tumor; Prone Position; Robotic Assisted Partial Nephrectomy

Summary: the goal of this clinical trial is to investigate whether robot-assisted laparoscopic partial nephrectomy by extraperitoneal approach in the prone position had any advantages over the traditional lateral position. the main questions it aims to answer are: is prone surgery safe and feasible, and what are the advantages over the traditional lateral position? does surgery in the prone position have an impact on the patients\&#39; prognosis? researchers will compare prone position to lateral position to see if robot-assisted laparoscopic partial nephrectomy by extraperitoneal approach in the prone position has any advantages over the traditional lateral position and whether it has any significant effect on the prognosis of the patients. participants will be randomly allocated 1:1 to two groups: prone position group and lateral position group. the enrolled patients will be underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach according to the corresponding positions of their groups. demographic indicators and perioperative-related indicators will be counted and recorded. ct or mri and related biochemical examinations will be reviewed at 1 month, 3 months, 6 months and 1 year after surgery, and every 1 year thereafter. the similarities and differences of the indicators in different positions will be analysed, and subgroup analyses will be performed according to the corresponding results.


Eligibility criteria:
inclusion criteria: 1. . patients with preoperative imaging suggestive of renal occupancy; 2. . sex is not limited; 3. . age ≥18 years; 4. . clinical staging consistent with indications for partial nephrectomy; 5. . suitable for robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach as judged by relevant preoperative clinical data; 6. . agree to provide basic clinical information and pathological and imaging data for scientific research and sign an informed consent form; 7. . agree to provide monitoring results during the follow-up recurrence monitoring process. exclusion criteria: 1. . patients who did not meet the indications for partial nephrectomy and did not undergo robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach; 2. . patients who refuse to undergo or cannot tolerate surgery in the appropriate position; 3. . patients with incomplete documentation of relevant data to provide accurate demographic, perioperative, and prognostic data; 4. . any condition which, in the opinion of the investigator, may be detrimental to the subject or result in the inability of the subject to meet or perform the requirements of the study; 5. . patients who are unable to provide written informed consent;